Grifols’ Q4 20 top line and bottom line came under pressure as limited plasma collection and the postponement of elective surgeries weighed on the performance of the Bioscience segment. Although robust growth in the Diagnostics segment provided some respite, the change in ASFA rules have delayed Grifols’ Alzheimer’s dream, which further aggravated the pain. Competition from FcRN-based drugs in the CIDP space is brewing and this is also bothersome.
